載入...
An osteopontin/CD44 immune checkpoint controls CD8(+) T cell activation and tumor immune evasion
Despite breakthroughs in immune checkpoint inhibitor (ICI) immunotherapy, not all human cancers respond to ICI immunotherapy and a large fraction of patients with the responsive types of cancers do not respond to current ICI immunotherapy. This clinical conundrum suggests that additional immune chec...
Na minha lista:
| 發表在: | J Clin Invest |
|---|---|
| Main Authors: | , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
American Society for Clinical Investigation
2018
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6264631/ https://ncbi.nlm.nih.gov/pubmed/30395540 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI123360 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|